Page 37 of 110: studies 361 to 370 of 1,096, newest first. Back to the 5-MeO-DMT overview
Imaging Neuroscience September 29, 2025 Klemens Egger, Daniel Meling, Firuze Polat et al. 1 citation
Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat.
Cell Reports July 22, 2025 Christof Koch 1 citation
Blackburne et al. track the electroencephalogram activity of volunteers inhaling a high dose of the powerful psychedelic 5-methoxy-N,N-dimethyltryptamine, revealing profoundly slowed-down brain activity but no significant reduction of alpha band power that is typical of other psychedelics.1.
Journal of Analytical Toxicology July 9, 2025 Jade Pullen, Robert J. Moore, Rebecca Wood et al. 1 citation
N, N-dimethyltryptamine (DMT) is a hallucinogen found in the South American Psychotria viridis plant and is the major psychoactive ingredient in the brew ayahuasca. In this report we performed a review of the surrounding literature and detail two deaths which recently occurred in the UK following DMT use. A literature search of both academic (PubMed, GoogleScholar) and media (using Google...
ACS Medicinal Chemistry Letters June 12, 2025 Robert B. Kargbo 1 citation
Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric...
American Journal of Psychiatry 2025 Johannes G. Ramaekers, Johannes T. Reckweg, Natasha L. Mason 25 citations
Unlike classical antidepressants, psychedelics such as psilocybin have been shown to induce a rapid antidepressant response. In the wake of this development, interest has emerged in ultra-fast, short-acting psychedelics such as 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and N,N-dimethyltryptamine (DMT) with the expectation that these can produce rapid antidepressant effects following an...
December 1, 2024 Chloe Lily West Jacobs
This dissertation explores the lasting impact of psychedelic use on brain networks, ranging from basic sensory processing to abstract mystical experiences. Recent research has highlighted the potential of these substances for treating psychiatric disorders, with therapeutic effects persisting weeks after a single dose. We focus on serotonergic psychedelics such as psilocybin and LSD, which are...
Pharmacological Research September 1, 2024 Giorgia Caspani, Simon Ruffell, WaiFung Tsang et al. 13 citations
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around their partial agonism at the serotonin 2 A receptor, leading to enhanced neuroplasticity and brain connectivity changes that underlie positive mindset shifts. However, these accounts fail to recognise that the gut microbiota, acting via the gut-brain...
Addiction Biology April 1, 2024 Stephan Tap 12 citations
Abstract Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment options show modest efficacy and relapse rates are high. Furthermore, there are increases in the treatment gap and few new medications have been approved in the past 20 years. Recently, psychedelic‐assisted therapy with psilocybin and lysergic acid...
Trends in biochemical sciences March 1, 2024 Abhishek K. Sen, J. Andrew Jones 2 citations
A recent report by Chen et al. describes the discovery of RmNMT, a highly active and promiscuous tryptamine N-methyltransferase from the cane toad, Rhinella marina. N,N-dimethyltryptamine derivatives produced by this enzyme were then evaluated for their potential to serve as next-generation treatments for mental health disorders.
Journal of Psychoactive Drugs 2024 Kelan Thomas, Robert L. Jesse, Nicky J. Mehtani et al. 4 citations
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level legalization of one or more psychedelic substances, usually referencing data from clinical trials as reasons to support liberalizing drug control policies. As psychedelic policies continue to be drafted, personal possession limits may be considered for...